This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Email citation

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2018 Jun 28;378(26):2531-2532.

doi: 10.1056/NEJMe1805733.

Progress in Nonmetastatic Prostate Cancer

Matthew R Smith¹

Affiliations

PMID: 29949488
DOI: 10.1056/NEJMe1805733

Editorial

Progress in Nonmetastatic Prostate Cancer

Matthew R Smith. N Engl J Med. 2018.

. 2018 Jun 28;378(26):2531-2532.

doi: 10.1056/NEJMe1805733.

Author

Matthew R Smith¹

Affiliation

¹ From the Massachusetts General Hospital Cancer Center, Boston.

PMID: 29949488
DOI: 10.1056/NEJMe1805733

No abstract available

PubMed Disclaimer

Comment on

Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer.
Hussain M, Fizazi K, Saad F, Rathenborg P, Shore N, Ferreira U, Ivashchenko P, Demirhan E, Modelska K, Phung D, Krivoshik A, Sternberg CN. Hussain M, et al. N Engl J Med. 2018 Jun 28;378(26):2465-2474. doi: 10.1056/NEJMoa1800536. N Engl J Med. 2018. PMID: 29949494 Free PMC article. Clinical Trial.

Similar articles

Re: Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time.
Taneja SS. Taneja SS. J Urol. 2014 Aug;192(2):421-2. doi: 10.1016/j.juro.2014.05.077. Epub 2014 May 14. J Urol. 2014. PMID: 25034990 No abstract available.
Re: A Multicentre Study of 5-Year Outcomes following Focal Therapy in Treating Clinically Significant Nonmetastatic Prostate Cancer.
Taneja SS. Taneja SS. J Urol. 2019 Mar;201(3):443-444. doi: 10.1097/01.JU.0000553702.58176.00. J Urol. 2019. PMID: 30759674 No abstract available.
Hormonal Treatment for Nonmetastatic Disease Recurrence After Curative Treatment of Prostate Cancer: Only for a Select Few.
Tilki D, Evans CP. Tilki D, et al. Eur Urol. 2016 May;69(5):821-2. doi: 10.1016/j.eururo.2015.12.008. Epub 2015 Dec 21. Eur Urol. 2016. PMID: 26719013 No abstract available.
High risk biochemical relapse and the timing of androgen deprivation therapy.
Ryan CJ, Small EJ. Ryan CJ, et al. J Urol. 2006 Dec;176(6 Pt 2):S61-5. doi: 10.1016/j.juro.2006.06.072. J Urol. 2006. PMID: 17084171 Review.
Rising PSA in nonmetastatic prostate cancer.
Moul JW, Bañez LL, Freedland SJ. Moul JW, et al. Oncology (Williston Park). 2007 Nov;21(12):1436-45; discussion 1449, 1452, 1454. Oncology (Williston Park). 2007. PMID: 18077992 Review.

See all similar articles

Cited by

Apalutamide, Darolutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC): A Critical Review.
Cattrini C, Caffo O, De Giorgi U, Mennitto A, Gennari A, Olmos D, Castro E. Cattrini C, et al. Cancers (Basel). 2022 Mar 31;14(7):1792. doi: 10.3390/cancers14071792. Cancers (Basel). 2022. PMID: 35406564 Free PMC article. Review.
Precision Targets for Intercepting the Lethal Progression of Prostate Cancer: Potential Avenues for Personalized Therapy.
Christenson M, Song CS, Liu YG, Chatterjee B. Christenson M, et al. Cancers (Basel). 2022 Feb 11;14(4):892. doi: 10.3390/cancers14040892. Cancers (Basel). 2022. PMID: 35205640 Free PMC article. Review.
Nonmetastatic castration-resistant prostate cancer treated with salvage focal brachytherapy after external beam radiotherapy.
Yoshida S, Matsuoka Y, Toda K, Uehara S, Tanaka H, Yokoyama M, Saito K, Yoshimura R, Fujii Y. Yoshida S, et al. IJU Case Rep. 2021 May 3;4(4):228-230. doi: 10.1002/iju5.12294. eCollection 2021 Jul. IJU Case Rep. 2021. PMID: 34258534 Free PMC article.
Management of Nonmetastatic Castration-Resistant Prostate Cancer: Recent Advances and Future Direction.
Esther J, Maughan BL, Anderson N, Agarwal N, Hahn AW. Esther J, et al. Curr Treat Options Oncol. 2019 Feb 11;20(2):14. doi: 10.1007/s11864-019-0611-z. Curr Treat Options Oncol. 2019. PMID: 30741354 Review.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information